BACKGROUND: Surfactant protein-D (SFTPD) is a component of the lung innate immunity that enhances clearance of pathogens and modulates inflammatory responses. An inverse association of putative, lung-derived circulating SFTPD with obesity has been reported but no information is available concerning possible SFTPD gene expression in human adipose tissue. METHODS: SFTPD gene expression was analyzed in human omental (OM; n ¼ 156) and subcutaneous (SC; n ¼ 106) adipose tissue, and in isolated fat cells (n ¼ 12) in association with measures of obesity and glucose tolerance. RESULTS: SFTPD gene was expressed in human adipose tissue and adipocytes. This expression was decreased in OM and SC adipose tissue from obese subjects with ( À 47%, Po0.0001; and À 37%, P ¼ 0.048) and without ( À 34%, P ¼ 0.001; and À 22%, P ¼ 0.08; respectively) type 2 diabetes when compared with the control group. Indeed, OM SFTPD was inversely associated with body mass index (r ¼ À 0.33, Po0.0001), percent fat mass (r ¼ À 0.36, Po0.0001), waist perimeter (r ¼ À 0.26, P ¼ 0.002), diastolic blood pressure (r ¼ À 0.21, P ¼ 0.018) and fasting glucose (r ¼ À 0.21, P ¼ 0.012); and positively linked to the expression of insulin receptor substrate 1 (IRS1; r ¼ 0.25, P ¼ 0.004), perilipin A (PLIN; r ¼ 0.38, P ¼ 0.007) and fatty acid synthase (FASN; r ¼ 0.36, Po0.0001). Accordingly, increased SFTPD (4.5-fold, P ¼ 0.02) was detected in isolated adipocytes when compared with the stromalvascular cell fraction, in parallel to IRS1, FASN and PLIN. CONCLUSIONS: Both OM and SC adipose tissue (mainly mature adipocytes) express SFTPD. This expression decreases with obesity and impaired glucose tolerance.
INTRODUCTION
Obesity is one of the most common public health problems facing the world today. It is well established that the size of adipose tissue depots around the omentum and in subcutaneous (SC) fat is related to higher risk of obesity-related comorbidities, including insulin resistance, type 2 diabetes (T2D) and dyslipidemia. 1 Obesity may be promoted by a multitude of different stimuli, such as energy intake and/or expenditure, central appetite regulation, and modulation of adipocyte and macrophage function in adipose tissue depots. 2 These findings pointed out that obesity represents a chronic inflammatory condition in adipose tissue, 3 and that the differentiation of adipocytes and the lipogenic capacity is altered in response to this inflammation, contributing to the pathogenesis of obesity-related comorbidities. 4 Surfactant protein-D (SFTPD) is a key factor of the innate immunity system, which develops its principal activity in lungs protecting from inhaled microorganisms, organic antigens and toxins. 5 SFTPD modulates leukocyte action, contributes to the inflammatory response, 6 and interacts with compounds such as bacterial lipopolysaccharides, oligosaccharides and fatty acids. 7 In addition to the pulmonary epithelium, other tissues, such as the brain, the pancreas, the gut and the endothelium, express the SFTPD gene. 8 The widespread distribution suggests potential new pathways, in which SFTPD may affect not only the specific inflammatory response but also systemic metabolism. Indeed, previous scientific evidence has revealed an association of low circulating SFTPD with increased fat accumulation, 9 and decreased insulin sensitivity. 10 However, the nature of the relation between this host defense collectin and metabolic disturbances is currently not well understood.
The study performed by Stidsen et al. 11 identified a set of metabolic variables, which were affected by SFTPD deficiency, including increased obesity. According to their data, body mass development in SFTPD-deficient mice was significantly increased compared with the corresponding wild type during ad libitum and fixed energy intakes. 11 They also identified the significant redistribution of body fat in parallel to obesity-related insulin resistance, as well as increased metabolic endotoxemia associated with the SFTPD deficiency in this model. 11 Given all this evidence suggesting the relationship between SFTPD and obesity, we hypothesized that human adipose tissue might express SFTPD, and that alterations in the expression of this collectin may be associated with the risk of developing obesityrelated metabolic disturbances such as insulin resistance and T2D. As a secondary hypothesis, we also explored whether a gene 1 polymorphism previously associated with circulating SFTPD did also correlate with SFTPD gene expression in adipose tissue.
MATERIALS AND METHODS

Subjects and samples
A total of 156 omental (OM) and 106 SC adipose tissue samples (80 OM and SC adipose samples from same subjects) were obtained from a group of subjects (n ¼ 187) who were invited to participate at the Endocrinology Service of the Hospital Universitari de Girona Dr Josep Trueta (Girona, Spain) and of the Hospital Carlos Haya de Málaga (Málaga, Spain). These adipose tissue samples were obtained during elective surgical procedures (cholecystectomy, abdominal hernia repair and gastric by-pass surgery), washed, fragmented and immediately flash-frozen in liquid nitrogen before being stored at -80 1C. All subjects were of Caucasian origin and reported that their body weight had been stable for at least 3 months before the study. They had no systemic disease other than T2D and/or obesity. All were free of any infections within the previous month before the study. Liver disease and thyroid dysfunction were specifically excluded by biochemical work-up. Other exclusion criteria for those patients included the following: (i) clinically significant hepatic, neurological or other major systemic disease, including malignancy; (ii) history of drug or alcohol abuse, defined as 480 g per day, or serum transaminase activity more than twice the upper limit of normal; (iii) elevated serum creatinine concentration; (iv) acute major cardiovascular event in the previous 6 months; (v) acute illnesses and current evidence of chronic inflammatory or infectious diseases; and (vi) mental illness rendering the subjects unable to understand the nature, scope and possible consequences of the study. All subjects gave written informed consent after the purpose of the study was explained to them.
Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Bioelectric impedance was used to estimate body fat composition in those subjects who agreed. According to these anthropometric parameters subjects were classified as non-obese (BMIo30 kg m À 2 ) and obese (BMIX30 kg m À 2 , and body fat % X25% for men and X35% for women). Blood pressure was measured in the supine position on the right arm after a 10-min rest. A standard sphygmomanometer of appropriate cuff size was used and the first and fifth phases were recorded. Values used in the analysis are the average of three readings taken at 5-min intervals. Patients were requested to withhold alcohol and caffeine during at least 12 h before the different tests.
The serum glucose levels were measured in duplicate by the glucose oxidase method with a Beckman Glucose Analyzer 2 (Beckman Coulter, Brea, CA, USA). The coefficient of variation was 1.9%. Total serum cholesterol was measured through the reaction of cholesterol esterase/ oxidase/peroxidase using a BM/Hitachi 747-200 Automatic Analyzer (Boehringer Mannheim, Indianapolis, IN, USA). Low-density and highdensity cholesterol were quantified after precipitation with polyethylene glycol at room temperature. Total serum triglycerides were measured through the reaction of glycerol phosphate oxidase and peroxidase.
Approximately 5 g of fresh samples of OM adipose tissue from 12 obese (BMI ¼ 43.7±6.5 kg m À 2 , age ¼ 44±13 years (mean±s.d.)) and normotolerant women were aseptically isolated and all visible connective tissue was removed. Tissues were finely minced and subjected to a 1-h digestion at 37 1C in a shaking water bath. The digestion buffer included 100 mM HEPES (Sigma-Aldrich, St Louis, MO, USA), 120 mM NaCl, 50 mM KCl, 5 mM D-glucose, 1 mM CaCl 2 , 1.5% type-V bovine serum albumin (Sigma-Aldrich), 2% P/S and 0.075% collagenase type I (Sigma-Aldrich) solution. The collagenase type I solution used to isolate stromal-vascular cells (SVCs) and mature adipocytes (MAs) from fat samples contained approximately 1.5 mg collagenase type I per ml (CLS type 1, Worthing Biochemical Corp., Lakewood, NJ, USA). The remaining procedure was similar to a previously described method for isolating SVCs from adipose tissue. 12 Gene expression analyses RNA was prepared from both fat biopsies and cellular debris using RNeasy Lipid Tissue Mini Kit (QIAgen, Gaithersburg, MD,USA). The integrity of each RNA sample was checked with an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Total RNA was quantified by means of a spectrophotometer (GeneQuant, GE Health Care, Piscataway, NJ, USA). A measure of 3 mg of RNA were reverse transcribed to cDNA using High Capacity cDNA Archive Kit (Applied Biosystems, Darmstadt, Germany), according to the manufacturer's protocol.
Gene expression was assessed by real-time PCR using the LightCycler 480 Real-Time PCR System (Roche Diagnostics, Barcelona, Spain), and the TaqMan technology suitable for gene expression quantification. The reaction was performed following manufacturers' protocol in a final volume of 7 ml. The cycle program consisted of an initial denaturing of 10 min at 95 1C then 45 cycles of 15 s denaturizing phase at 92 1C, and 1 min annealing and extension phase at 60 1C. Replicates as well as positive and negative controls were included in all reactions.
The commercially available and pre-validated TaqMan primer/probe sets used were as follows: Cyclophilin A (PPIA; 4333763) was used such as endogenous control in each reaction and surfactant protein-D (SFTPD; Hs01108490_m1), insulin receptor substrate 1 (IRS1; Hs00178563_m1), leptin (LEP; Hs00174877_m1), perilipin 2 (PLIN2; Hs00605340_m1) and fatty acid synthase (FASN; Hs00188012_m1) were the target genes. The Second Derivative Maximum Method was used for the determination of the crossing points (Cp). A Cp value was obtained for each amplification curve and DCp value was first calculated by subtracting the Cp value for human PPIA cDNA from the Cp value for each sample and transcript. Fold changes compared with the endogenous control were then determined by calculating 2 À DCp , so gene expression results are expressed in all cases as expression ratio relative to the endogenous control expression, according to manufacturers' instructions.
SFTPD protein analyses by ELISA
To evaluate protein levels of SFTPD in human samples of adipose tissue, we used a solid phase sandwich ELISA that detects endogenous levels of total SFTPD (HyCult biotechnology b.v.; PB Uden, The Netherlands) in OM and SC adipose tissue from 15 consecutive participants (4 non-obese and 11 obese individuals). After incubation with protein lysates from 100 mg of adipose tissue treated with the radioimmunoprecipitation assay (Cell Signaling, Beverly, MA, USA) lysis buffer, measures of total SFTPD protein were captured by the coated antibody. Following extensive washing procedures, mouse antibodies were added to detect the captured total SFTPD protein. Horseradish peroxidase substrate-linked anti-mouse antibody was then used to recognize the bound detection antibody. Horseradish peroxidase substrate (3,3 0 ,5,5 0 -tetramethylbenzidine base) was added to develop color. The magnitude of absorbance for this developed color (450 nm) was proportional to the quantity of SFTPD protein in protein lysates of human OM adipose tissue.
Genetic analyses
The single-nucleotide polymorphism (SNP) rs1885551 (NC_000010.10: g.81712353A4G) is tagging for the promoter region as a major LD block in SFTPD. It appears to be strongly associated with serum SFTPD concentrations and SFTPD gene expression in lung. 13 Genomic DNA was purified from peripheral blood leukocytes from 75 randomly selected participants using QIAmp Blood kits (QIAgen) and quantified by means of a spectrophotometer (GeneQuant, GE Health Care). A measure of 100 ng of DNA were used for PCR amplification and genotyped using an allelic discrimination assay (C__12124527_20) and the ABI Prism 7000 sequence detector (Applied Biosystems, Foster City, CA, USA). The reaction was performed in a final volume of 25 ml. DNA was amplified after 50 cycles with an initial denaturation of 10 min at 95 1 C. The cycle program consisted of 15 s denaturation at 92 1C and 1 min annealing and extension at 60 1C. Positive and negative controls, which were correctly identified, were included in all reactions. Successful genotyping was accomplished in more than 99% of subjects.
Statistical analyses
Descriptive results of continuous variables are expressed as mean±s.d. Before statistical analysis, normal distribution and homogeneity of the variances were evaluated using Levene's test. Variables were given a base Log 10 -transformation when necessary. These parameters were analyzed and tested for significance on this Log 10 -scale. The anti-log-transformed values of the means (geometric mean) are reported in the table and in plots. The relation between variables was tested using Pearson's test and stepwise multiple linear regression analysis. Analysis of variance and the unpaired t-tests were used for comparisons of quantitative variables between groups. Chi-square test was used for categorical variables. The statistical analyses were performed using the program SPSS (version 13.0; IBM, Chicago, IL, USA).
RESULTS
SFTPD expression in human adipose tissue
Expression of SFTPD, IRS1, GLUT4, LEP, PLIN and FASN genes was quantified in SC and OM adipose tissue from a final cohort of 187 consecutive unselected participants, 80 paired adipose samples from the same patient. The anthropometric and metabolic characteristics of the participants included in this cross-sectional study are shown in Table 1 .
SFTPD gene expression was significantly decreased in both OM and SC adipose tissues from obese subjects ( À 34%, P ¼ 0.001, Figure 1a ; and À 22%, P ¼ 0.08; Figure 1c , respectively) when compared with non-obese individuals. These differences were of special significance when the expression levels of obese subjects with T2D were compared with those found for the control group ( À 47%, Po0.0001; Figure 1a ; and À 37%, P ¼ 0.048; Figure 1c, respectively). Indeed, OM SFTPD gene expression was significant and inversely associated with BMI (r ¼ À 0.33, Po0.0001; Figure 1b ), percent fat mass (r ¼ À 0.36, Po0.0001), waist perimeter (r ¼ À 0.26, P ¼ 0.002), diastolic blood pressure (r ¼ À 0.21, P ¼ 0.018) and fasting glucose (r ¼ À 0.21, P ¼ 0.012). On the other hand, OM SFTPD was also significant but positively associated with SC SFTPD (r ¼ 0.67, Po0.0001), IRS1 (r ¼ 0.25, P ¼ 0.004; Figure 2a) , PLIN (r ¼ 0.38, P ¼ 0.007) and the expression levels of FASN (r ¼ 0.36, Po0.0001; Figure 2b ) in OM adipose tissue. We also found an inverse association with leptin (LEP; r ¼ À 0.22, P ¼ 0.036). Similar findings were identified for SC SFTPD expressions (Figure 1d) .
As mRNA levels may not necessarily predict the translated protein levels, SFTPD protein in OM and SC adipose tissue was obtained by ELISA in a randomized subpopulation of 15 individuals (4 non-obese and 11 obese individuals; Table 1 ). SFTPD protein levels in human adipose tissue were in the range of 2.5 ± 1.5 ng mg À 1 of tissue. Indeed, measurements of total SFTPD protein in OM ( À 46%, P ¼ 0.048) and SC ( À 58%, P ¼ 0.041) adipose tissue from this subpopulation corroborated the decreased SFTPD levels in fat depots from obese subjects. adipose tissue (4.5-fold, P ¼ 0.02; Figure 3a) , in parallel to the increased expression of FASN (41-fold, Po0.0001; Figure 3b ), PLIN and IRS1 (4.7-fold, P ¼ 0.01; Figure 3c ).
Association of SNP rs1885551 with SFTPD expression in human adipose tissue To further validate gene expression results in human adipose tissue, the effect of a common SNP previously associated with SFTPD expression (rs1885551) was evaluated in a randomly selected subsample of 75 consecutive subjects (17 G allele carriers and 58 AA homozygotes; Table 1 ) from whom genomic DNA was available. In agreement with a previous report regarding circulating SFTPD, 13 we found an increased expression of adipose tissue SFTPD in both OM ( þ 105%, P ¼ 0.001; Figure 4a ) and SC ( þ 51%, P ¼ 0.046; Figure 4b ) from AA carriers, independently of measures of glucose tolerance (Table 1) . Indeed, multiple linear regression analyses to predict SFTPD gene expression in adipose tissue revealed that this polymorphism (P ¼ 0.022) contributed independently to explain 9.5% (P ¼ 0.05) of OM SFTPD variance after controlling for BMI (P ¼ 0.068) and fasting glucose (P ¼ 0.578). Interestingly, decreased BMI (40.3±9.5 vs 45.7± 7.2 mg dl À 1 , P ¼ 0.004; Figure 4c ) and % fat mass (50.7 ± 12.9 vs 57.6 ± 9.6%, P ¼ 0.006; Figure 4d ) were found for this cohort in AA individuals when compared with G-allele carriers. Thus, here again the higher the SFTPD gene expression, the lower the fat mass.
DISCUSSION
Over nutrition and sedentary activities, in combination with further external injuries, compromise the homeostasis of the innate immune system, which is commonly associated with chronic inflammation, a common feature of obese subjects intrinsic to the metabolic syndrome. 14, 15 In the current work, the study of SFTPD expression in human adipose tissue was considered of interest to evaluate the underlying mechanisms connecting obesity, insulin resistance, inflammation and circulating SFTPD, previously known to be significantly decreased in obese subjects. 9, 10 We then confirmed SFTPD gene expression at the protein level and we further study SFTPD in adipose tissue fractions. Thereby, we provide data suggesting that human adipose tissue and adipocytes express SFTPD in close association with gene markers of insulin sensitivity and lipogenesis, such as the IRS1, PLIN and FASN gene expression. Interestingly, SFTPD expression was inversely related to measures of obesity and glucose tolerance, and was higher in mature adipocytes than in SVCs. This is, to our knowledge, the first evidence that a specific lung innate immune protein (SFTPD) is expressed in human adipose tissue and adipocytes. The surfactant immune function is primarily attributed to SFTPA and D proteins. These proteins opsonize pathogens, which will be uptaken by phagocytes, regulating the inflammatory response and interacting with the adaptive immune response, being involved in the defense against infection. 16 It is known that abnormalities in pulmonary function are risk factors for the development of T2D, 17 as well as overweight and obesity are for pulmonary diseases. 18 Indeed, inflammatory responses in the lung might influence adipocyte production of adipokines such as adiponectin and leptin, thus conditioning systemic metabolism. However, the nature of the relation between SFTPD and metabolic disturbances is still largely unknown.
Changes in the expression pattern of SFTPD gene in human adipose tissue with obesity and insulin resistance suggests that SFTPD could contribute to insulin action in adipose tissue. Concurrently, in the setting of obesity, the production of adiponectin (another well-known anti-inflammatory collectin) in adipose tissue is decreased, in parallel to decreased adipose tissue lipogenic capacity 4 and the expression of markers of insulin action. There is accumulated evidence that abnormalities in the innate immune system may predict the development of obesity, 19 with adipocytes constituting both the source and target for inflammatory mediators, 20 although the causal relationship remains elusive. SFTPD is known to bind fatty acids and may modify the cellular uptake and catabolism of lipids, 21 so we speculate that both circulating and adipose tissue SFTPD might modulate post-prandial cytokine production affecting fat metabolism. We cannot exclude that impaired insulin action may also lead to decreased SFTPD expression in adipose tissue. In humans, fasting and post-OGTT glucose concentrations have been found to be negatively associated with circulating SFTPD. 10 At least two previous studies have demonstrated decreased circulating SFTPD in obese subjects. 9, 10 As a part of the Danish population-based twin study (GEMINAKAR) on the metabolic syndrome, the authors analyzed 1476 Danish twins. Serum SFTPD was significantly and inversely associated with weight (P ¼ 0.001) and waist circumference in men (Po0.001) and to BMI in both genders (P ¼ 0.039 women, Po0.001 men). Similar findings were obtained in a Spanish cohort. 10 Despite the relative unknown role of SFTPD in energy metabolism and energy homeostasis, recent studies demonstrated that SFTPD knock-out mice were mildly obese, showing higher food intake but not increased energy expenditure when compared with wild-type mice. 11 Then, the lack of SFTPD in this model induced increased accumulation of adipose tissue and led to obesity-related insulin resistance, suggesting that SFTPD, even circulating or SFTPD in adipose tissue, may regulate body composition to some extent, playing a causal role at the crosstalk between energy intake and obesity. The associations found in our study support this observation in humans.
At this respect, AA homozygosis for a SNP (rs1085551) affecting SFTPD gene expression seems to have lower risk of developing obesity than G allele carriers. As this genotype is associated with increased circulating 13 and SFTPD gene expression (current data), the putative presence of this collectin in adipose tissue could be protective to some extent, at least during the progression of inflammation and the development of obesity. However, the SNP association results should be taken with caution before replicated in a larger cohort. Indeed, a limitation of our study is that small significant differences for genetic studies might have been detected with larger groups of subjects. On the other hand, some of the results presented here should be considered 'nominally' significant due to the use of so many subgroups. Another limitation is that the specific effect of SFTPD on inflammation and insulin sensitivity in adipose tissue and/or adipocytes has not been properly elucidated here.
In summary, the findings reported here revealed that human adipose tissue and adipocytes express SFTPD, and that this expression is decreased in obese subjects when compared with non-obese subjects, especially in those subjects with T2D. The higher expression of this collectin in non-obese subjects suggests its possible implication in adipose tissue insulin sensitivity and lipogenesis to some extent. Further investigations will be required to evaluate the functional consequences of these associations, as well as the specific relationship between SFTPD and adipose tissue insulin action, which remains elusive.
